Elicio Therapeutics reports incentive grants

BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies to treat cancer, today announced that on September 16, 2024, Elicio granted a total of 4,800 incentive stock options to a new employee as an incentive to the individual entering into employment with Elicio pursuant to Nasdaq Listing Rule 5635(c)(4). The incentive stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under Elicio Therapeutics, Inc.’s 2024 Incentive Award Plan.

The grant provides for the acquisition of shares of Elicio’s common stock at a price of $4.13 per share, being the closing price per share of Elicio’s common stock as reported by Nasdaq on September 16, 2024, the date of the grant.